Skip to content

Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury

Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury (EVA-Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00786292
Acronym
EVA
Enrollment
Unknown
Registered
2008-11-06
Start date
2009-07-31
Completion date
2012-09-30
Last updated
2012-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lung Injury

Brief summary

Variable pressure support during assisted spontaneous breathing (noisy PSV) has been shown to improve the respiratory function in experimental acute lung injury (ALI). We aimed at comparing the effects of noisy PSV with traditional PSV on the respiratory function of patients suffering from ALI.

Interventions

OTHERAssisted mechanical ventilation

Patients will be mechanically ventilated with noisy PSV and PSV in random sequence

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age 18 to 75 yrs * 150 mmHg \< PaO2/FIO2 \< 300 mmHg * mechanical ventilation with PSV or BIPAP * less than 15 days of mechanical ventilation * at least 20% of minute ventilation originated from spontaneous breathing

Exclusion criteria

* BMI \> 35 * esophageal disease * neuromuscular disease * instable thorax * pneumothorax * head trauma * brain injury * increased intracranial pressure * agitation * increased need for vasoactive drugs * chronic lung disease * acute coronary disease * participation in another clinical trial within the last 4 weeks at enrollment Interruption criteria: * acute change of mental status * SaO2 \< 92% * pHa \< 7.30 * respiratory rate \> 30 or \< 6 /min * dyspnea * diaphragm/thorax antagonism * diaphoresis * abnormal use of respiratory muscles * increase of the heart rate above 120% of baseline or absolute value \< 60 or \> 130 /min * mean arterial pressure above 120% of baseline or absolute value \< 70 or \> 110 mmHg

Design outcomes

Primary

MeasureTime frame
Effect on the arterial oxygenation

Secondary

MeasureTime frame
Effect on the work of breathing
Effect on PaCO2

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026